Literature DB >> 9531310

Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.

Q Ning1, D Brown, J Parodo, M Cattral, R Gorczynski, E Cole, L Fung, J W Ding, M F Liu, O Rotstein, M J Phillips, G Levy.   

Abstract

Ribavirin, a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses. It has been previously shown to attenuate the course of fulminant hepatitis in mice produced by murine hepatitis virus strain 3. We therefore studied the effects of ribavirin on murine hepatitis virus strain 3 replication, macrophage production of proinflammatory mediators including TNF, IL-1, and the procoagulant activity (PCA), fgl2 prothrombinase; and Th1/Th2 cytokine production. Although ribavirin had inhibitory effects on viral replication (<1 log), even at high concentrations complete eradication of the virus was not seen. In contrast, at physiologic concentrations (up to 500 microg/ml), ribavirin markedly reduced viral-induced parameters of macrophage activation. With ribavirin treatment, the concentrations of PCA, TNF-alpha and IL-1beta all decreased to basal concentrations: PCA from 941 +/- 80 to 34 +/- 11 mU/10(6) cells; TNF-alpha from 10.73 +/- 2.15 to 2.74 +/- 0.93 ng/ml; and IL-1beta from 155.91 +/- 22.62 to 5.74 +/- 0.70 pg/ml. The inhibitory effects of ribavirin were at the level of gene transcription as evidenced by Northern analysis. Both in vitro and in vivo, ribavirin inhibited the production of IL-4 by Th2 cells, whereas it did not diminish the production of IFN-gamma in Th1 cells. In contrast, ribavirin had no inhibitory effect on TNF-alpha and IL-1beta production in LPS-stimulated macrophages. These results suggest that the beneficial effects of ribavirin are mediated by inhibition of induction of macrophage proinflammatory cytokines and Th2 cytokines while preserving Th1 cytokines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531310

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  78 in total

1.  Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation.

Authors:  D G Bausch; P E Rollin; A H Demby; M Coulibaly; J Kanu; A S Conteh; K D Wagoner; L K McMullan; M D Bowen; C J Peters; T G Ksiazek
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  Current Views on Hepatitis C Virus Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

3.  Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1).

Authors:  Sotirios G Zarogiannis; James W Noah; Asta Jurkuvenaite; Chad Steele; Sadis Matalon; Diana L Noah
Journal:  Life Sci       Date:  2012-01-16       Impact factor: 5.037

4.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Authors:  Helen S Te; Glenn Randall; Donald M Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 5.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

Review 6.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 7.  Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.

Authors:  Gillian M Keating; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin.

Authors:  T Watanabe; M Inoue; K Harada; N Homma; M Uchida; N Ogata; R Funada; K Hasegawa; K Soga; K Shibasaki
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

9.  Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B.

Authors:  Chuan-Long Zhu; Wei-Ming Yan; Fan Zhu; Yong-Fen Zhu; Dong Xi; De-Ying Tian; Gary Levy; Xiao-Ping Luo; Qin Ning
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

Review 10.  Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature.

Authors:  V Tahan; F Ozseker; D Guneylioglu; A Baran; R Ozaras; A Mert; A C Ucisik; T Cagatay; D Yilmazbayhan; H Senturk
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.